Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 601–700 of 793
Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019
Schjesvold, F. H. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13464 · Cited by 3
Novel Induction Regimens in Multiple Myeloma
Runcie, K. D., & Mark, T. M. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0282-1 · Cited by 2
Aznab, M., Rezaei, M., Navabi, J., & Moieni, A. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12418 · Cited by 2
Multiple Myeloma and Renal Failure
Tosi, P., Imola, M., Mianulli, A. M., Tomassetti, S., Molinari, A., Mangianti, S., Ratta, M., Merli, A., & Polli, V. (2015) · EMJ Oncology · doi:10.33590/emjoncol/10312540 · Cited by 2
Du, X., Jin, J., Cai, Z., Chen, F., Zhou, D., Yu, L., Ke, X., Li, X., Wu, D., Meng, F., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2069-8 · Cited by 4
“Using Rd in the MM-021 trial addressed any safety concerns related to the use of highdose dexamethasone in Chinese patients, and was consistent with the increasing use of lower doses of dexamethasone in combination with lenalidomide [5, 14].”
Offidani, M., Corvatta, L., Bringhen, S., Gentili, S., Troia, R., Maracci, L., Larocca, A., Gay, F., Leoni, P., & Boccadoro, M. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12834 · Cited by 2
“The FIRST trial (14) demonstrated that elderly patients treated with continuous lenalidomide– dexamethasone obtained a similar PFS compared to those patients receiving bortezomib–melphalan–prednisone, although head to head comparison was not performed.”
BackgroundResultInfluentialNovel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
Mian, H. S., & Wildes, T. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0539-1 · Cited by 2
Frail Patients with Newly Diagnosed Multiple Myeloma
Larocca, A., & Palumbo, A. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_27 · Cited by 2
Guérison du myélome multiple : un objectif envisageable à court terme ?
Facon, T. T. F. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30260-2 · Cited by 2
Self-citationMinimal residual disease in multiple myeloma 2019
Kunacheewa, C., Lin, P., & Manasanch, E. E. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.71 · Cited by 2
[Clinical features and prognosis of 93 elderly patients with multiple myeloma].
Chen, H. M., Zhou, F., Wei, W., Peng, R., Shi, H., & Hou, J. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.09.003 · Cited by 2
“[5] Benboubker L, Dimopoulos MA, Dispenzieri A, et al.”
BackgroundLuttwak, E., Gatt, M. E., Lebel, E., Lavi, N., Tadmor, T., Kreiniz, N., Benyamini, N., Horowitz, N. A., Geva, M., Suriu, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.002 · Cited by 2
Lee, B., Kang, K., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Park, Y., Choi, C. W., & Kim, B. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687361 · Cited by 2
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients
Tacchetti, P., Rocchi, S., Barbato, S., Zamagni, E., Pantani, L., Mancuso, K., Rizzello, I., & Cavo, M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1983426 · Cited by 2
Self-citationTumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
Alonso, R., & Lahuerta, J. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800309 · Cited by 2
“This downgrading of CR to VGPR in the absence of urine assessments led to an inappropriate reduction of CR rate in some clinical trials (39, 40), a relevant end-point for efficacy.”
MethodNavarro-Almenzar, B., Cabañas‐Perianes, V., & Belmonte, M. J. M. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.11.004 · Cited by 2
Manier, S., Dimopoulos, M. A., Hulin, C., Leleu, X. P., Delforge, M., Weisel, K. C., Mouro, J. L., Costa, B. A., Sturniolo, M., & Facon, T. T. F. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.06.002 · Cited by 2
Self-citationGroen, K., Schjesvold, F. H., van der Holt, B., Levin, M., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000940 · Cited by 2
Dew, A., Lin, J., Darmon, S., Roswarski, J., Shriver, C. D., Zhu, K., & Chiu, A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.06.008 · Cited by 2
O’Meara, K., Fansiwala, K. M., Kathuria‐Prakash, N., El‐Masry, M., & Oh, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03129-z · Cited by 2
“…myeloma given a favorable side effect profile, improvement in progression-free survival, and an overall survival benefit compared to the prior standard therapy (melphalan, prednisone, and thalidomide or bortezo-mib) in elderly patients who are ineligible for autologous stem cell transplant [3].”
BackgroundDai, Y., & Jin, F. (2016) · International Journal of Hematology and Therapy · doi:10.15436/2381-1404.15.008 · Cited by 3
“Again, IMiDs synergistically interact with dexamethasone to kill MM cells, which is consistent with numerous clinical findings[25].”
ResultPrediction of patients with multiple myeloma eligible for second- or third-line treatment in France
Rondeau, V., Cornet, É., Moreau, P., & Troussard, X. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2688-9 · Cited by 2
Self-citationFaiman, B. M., & Valent, J. N. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s90764 · Cited by 3
“The 4-year OS rate in the Rd continuous group was 59% compared to 51% among patients who received MPT. 45 The incidence of grade 3 side effects was lower in the continuous Rd group versus MPT group (85% vs 89%), primarily because of the higher incidence of neuropathy in the MPT versus Rd groups (9% vs 1% respectively).”
Myeloma care adaptations in the UK during SARS‐CoV‐2 pandemic: Challenges and measurable outcomes
Djebbari, F., Panitsas, F. P., Sharpley, F. A., Rampotas, A., Larham, J., Moore, S. E., Gooding, S., Kothari, J., & Ramasamy, K. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13479 · Cited by 2
Management of newly diagnosed transplant ineligible multiple myeloma
Atrash, S., Bhutani, M., Paul, B. A., Voorhees, P. M., & Usmani, S. Z. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1786558 · Cited by 3
Terebelo, H. R., & Reap, L. E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95819 · Cited by 2
Updates in the management of relapsed/refractory multiple myeloma
Hanna, K. S., Larson, S., Nguyen, J. M., Tu, S., Boudreau, J., & Rose, S. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211028906 · Cited by 2
“until disease progression, Rd in 28-day cycles for 72weeks, and melphalan/prednisone/thalidomide (MPT) in 42-day cycles for 72weeks.(25) Themedian duration of follow-up was 37months, at which time the median progression-free survival was 25.”
MethodInnovations in treatment and response evaluation in multiple myeloma
Wester, R., & Sonneveld, P. (2016) · Haematologica · doi:10.3324/haematol.2016.142737 · Cited by 3
“IMIDs such as lenalidomide and thalidomide have increased OS and PFS in newly diagnosed multiple myeloma (NDMM).(14,15)”
BackgroundCepicka, J., Sauer, L. D., Kirchner, M., Kieser, M., & Erdmann, S. (2025) · SoftwareX · doi:10.1016/j.softx.2025.102066 · Cited by 2
Bolaman, A. Z., Turgutkaya, A., Sahip, B., Selim, C., Küçükerdiler, H. E., Ertop, Ş., Sargın, G., & Yavaşoğlu, İ. (2021) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2020.2020.0169 · Cited by 1
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
Du, C., Li, L., Fan, H., Mao, X., Liu, J., Xu, Y., Sui, W., Deng, S., Li, C., Zhao, J., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2258686 · Cited by 5
“The result shows a comparable response rate with VRD in SWOG S0777, and a better PFS than continuous Rd of 25.5 months in the FIRST trial [32].”
ResultInfluentialSelf-citationde Arriba, F., Gironella, M., Garcia, M. T. H., Campos, J. A. S., Rodríguez, S. H., Belmonte, M. J. M., López, T. R., González-Pardo, M., Espinosa, M. C., & on behalf of the CARINAE Study Investigators (2024) · Pharmaceuticals · doi:10.3390/ph17101272 · Cited by 1
Blurring the Lines: Beyond Using Transplant Eligibility to Guide Induction Therapy in Myeloma
Pan, D., Kumar, A. D., Chung, A., & Chari, A. (2025) · The Hematologist · doi:10.1182/hem.v22.1.202524 · Cited by 1
Zhang, X., Greene, E. J., Bláha, O., & Wei, W. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802241313297 · Cited by 1
McCurdy, A. B. R., Gul, E., Reece, D. E., Chu, M. P., Jimenez-Zepeda, V. H., Louzada, M., Song, K., Mian, H. S., Sébag, M., White, D. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.02.011 · Cited by 2
Self-citationSong, F., Zhang, Q., Zhang, Z., Xu, T., Qin, H., Lou, Y., Zhang, W., Liu, F., Zhang, Y., & Huang, P. (2025) · The FASEB Journal · doi:10.1096/fj.202500857r · Cited by 1
Bringhen, S., Cani, L., Giuliani, N., Mangiacavalli, S., Benevolo, G., Antonioli, E., Zambello, R., Ria, R., Vincelli, I. D., Ronconi, S., et al. (2025) · Haematologica · doi:10.3324/haematol.2025.287510 · Cited by 1
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
“As both PFS and OS were shown to favor Rd over MPT among patients aged ≥ 75 years in the FIRST trial, this became the standard of care regimen in elderly MM patients [29,31].”
Zhao, S., Wellard, C. J., Moore, E., Spencer, A. G., Quach, H., Ho, P. J., McDonald, E.-J., Mollee, P. N., Harrison, S. J., Augustson, B. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.004 · Cited by 1
Burnett, J., Sychterz, C. J., Katz, J. B., Shakeel, F., Silva, J., Chen, W., Shahane, A., Wang, X., Lamba, M., & Gaudy, A. M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70082 · Cited by 3
Al-Ahmed, M. A., & Al-Rubaie, H. A. (2025) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_75_25 · Cited by 2
How to approach the high-risk myeloma from induction through relapse?
Weisel, K. C., Schaefers, C., & Leypoldt, L. B. (2025) · Hematology · doi:10.1182/hematology.2025000762 · Cited by 1
Self-citationFirst-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 2
Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O. A., Mewawalla, P., Shah, M. R., Lutfi, F. U., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050249 · Cited by 1
Optimizing the treatment of multiple myeloma
Morgan, G. J., & van Rhee, F. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.185 · Cited by 1
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
Fillitz, M., Seebacher, A., & Panny, M. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0206-8 · Cited by 1
Treatment of elderly patients with myeloma
Boyle, E. M., Legrand, C., Demarquette, H., Guidez, S., Herbaux, C., Leleu, X. P., & Facon, T. T. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6_4 · Cited by 1
Self-citationManagement of Elderly Patients with Plasma Cell Myeloma
Campagnaro, E. L., Goebel, T. E., & Lazarus, H. M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0265-x · Cited by 1
“The incidence of all grade 3 or higher toxicity was 70 % in the Rd arm and 78 % in the MPT arm [98, 99].”
BackgroundENDEAVOR to change treatment for multiple myeloma?
Scheid, C. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00531-8 · Cited by 1
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.
Helwick, C. (2016) · Europe PMC (PubMed Central) · Cited by 1
Richter, J. R., Biran, N., Vesole, D. H., & Siegel, D. S. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.007 · Cited by 1
Jose, W. M., Pavithran, K., & Ganesan, T. S. (2017) · Current Oncology · doi:10.3747/co.24.3574 · Cited by 1
Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Offidani, M., Corvatta, L., Gentili, S., Aghemo, E., Palumbo, A. P., Maracci, L., & Larocca, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_3 · Cited by 1
Treatment of t(4;14) and del(17p) in Multiple Myeloma
Sonneveld, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_4 · Cited by 1
Srinivasan, S. S., Elion‐Mboussa, A., & Yue, L. H. (2018) · ICSA book series in statistics · doi:10.1007/978-981-10-7820-0_17 · Cited by 1
VI. Standard Treatment for Multiple Myeloma
Ito, S., & Takano, M. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1238 · Cited by 1
Deng, S., Xu, Y., Sui, W. W., An, G. C., Mao, X. H., Li, Z. J., Zou, D. H., & Qiu, L. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.06.005 · Cited by 1
“[3] Benboubker L, Dimopoulos MA, Dispenzieri A, et al.”
BackgroundSelf-citationBest of 2017 in Multiple Myeloma
Raje, N. S., & Yee, A. J. (2018) · The Hematologist · doi:10.1182/hem.v15.1.8179 · Cited by 1
Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma
Touzeau, C. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00132-6 · Cited by 1
Ryabukhina, Y. E., Abbasbeyli, F. M., Zeynalova, P. A., Тимофеева, О. Л., Александровна, К. Н., & Жуков, А. Г. (2022) · MD-Onco · doi:10.17650/2782-3202-2022-2-3-28-35 · Cited by 1
Suzuki, T., Terada, M., Machida, R., Kataoka, T., Ito, Y., Kataoka, K., Maruyama, D., & Nagai, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac198 · Cited by 1
“(1) Simultaneous or metachronous (within 5 years) double cancer except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor or early stage cancers (2) Active infection requiring systemic therapy (3) Female during pregnancy, within 28 days of post parturition or during…”
BackgroundMethodInfluentialRath, C. G., Yoo, C., Cheplowitz, H., Lo, M., Young, R., Guglielmo, J., Saunders, I. M., Banerjee, R. K., Young, R. B., Kumar, A. D., et al. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221150935 · Cited by 1
“20 8, 21 In the current study, no speci fi c correlations were iden-ti fi ed between the seven pre-selected patient variables and duration of maintenance lenalidomide, despite controlling for time-dependent bias by excluding PD.”
BackgroundAdvanced practice nurse management in multiple myeloma treated with oral therapy
Sapet, M., Migala, C., Daguenet, É., Collet, P., Boussoualim, K., Thomas, T., Guyotat, D., & Augeul-Meunier, K. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.07.010 · Cited by 1
Suzuki, K., & Yano, S. (2023) · Life · doi:10.3390/life13112229 · Cited by 1
“…patients with NDMM, and Rd therapy was used until disease progression for transplantation-ineligible patients with NDMM in the FIRST trial, where salvage chemotherapy, including LEN, had to be one of the choices for second-line treatment, even if LEN was often used continuously [50,51].”
MethodRyabukhina, Y. E., Zeynalova, P. A., Abbasbeyli, F. M., Тимофеева, О. Л., Valiev, T. T., Александровна, К. Н., & Жуков, А. Г. (2023) · Oncohematology · doi:10.17650/1818-8346-2023-18-4-90-103 · Cited by 1
Nogai, A. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21207-9.00014-8 · Cited by 1
Haider, I., Pond, G. R., Cameron, R., Aljama, M. A., Kouroukis, T., Wong, K., Fiala, M. A., Wildes, T. M., & Mian, H. S. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101735 · Cited by 3
Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study
Ko, H., Han, S., Park, S., Choi, S., Byun, J. M., & Min, C. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.015 · Cited by 3
MM Therapy in Resource-Constrained Including Maintenance
Hungria, V. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00363-x · Cited by 1
Amsterdam, D., Grossberger, O., Melamed, N., Shpitzer, D., Trestman, S., Shragai, T., Cohen, Y. C., & Avivi, I. M. (2024) · Cancers · doi:10.3390/cancers16193329 · Cited by 1
“…the complete response (CR) rates in patients treated through clinical prospective studies were generally higher than that reported in our series [17], potentially due to the higher doses being administered and the better adherence to study treatment, which were feasible in patients eligible to…”
ResultLi, Z., Zhang, W., Huang, F., & Hao, S. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100575 · Cited by 1
Landgren, O., Biran, N., O’Donnell, E., Mikhael, J. R., Weisel, K. C., Broijl, A., Usmani, S. Z., Moreau, P., Gay, F., Mina, R., et al. (2025) · HemaSphere · doi:10.1002/hem3.70178 · Cited by 1
Self-citationConsolidation and Maintenance in De Novo First-Line Multiple Myeloma with Modern Agents
Stoppa, A. M., Coso, D., Fouquet, G., & Leleu, X. P. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.3 · Cited by 1
Uprety, D., Adhikari, J., Arjyal, L., Naglak, M. C., & Seidman, M. J. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.10.002 · Cited by 1
Renal insufficiency in patients with multiple myeloma
Bozic, B., Hölbling, S., Völkel, V., & Sebesta, C. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0343-3 · Cited by 1
“In the treatment of MM patients with renal insufficiency, immunomodulating substances (IMD) may also be used, such as lenalidomide in combination with high-dose dexamethasone [3].”
Treatment of Elderly Patients with Multiple Myeloma
Boyle, E. M., Facon, T. T. F., Mateos, M., & Palumbo, A. P. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_4 · Cited by 3
Self-citationTreatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 2
Self-citationGFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study
Schmidts, A., Grünewald, J., Kleber, M., Terpos, E., Ihorst, G., Reinhardt, H., Walz, G., Wäsch, R., Engelhardt, M. M., & Zschiedrich, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1626-7 · Cited by 1
Special problems in the management of elderly patients with multiple myeloma
Gay, F., & Larocca, A. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.027 · Cited by 1
“[32] Interestingly, continuous Rd treatment showed better clinically relevant health-related-quality-of-life measurements (HRQoL) over the course of treatment, and better QoL-related to treatment side effects as compared to MPT.[33] Therefore, the old standard MPT is no longer considered a first option.”
InfluentialTherapeutic benefits of lenalidomide in hematological malignancies
Abdulsalam, M. S., & Manimoliyan, D. V. (2019) · Indian Journal of Medical Specialities · doi:10.4103/injms.injms_8_19 · Cited by 1
Suzuki, K., Doki, N., Meguro, K., Sunami, K., Kosugi, H., Sasaki, O., Takagi, T., Murakami, H., & Shimizu, K. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02700-3 · Cited by 1
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Kumar, L. (2020) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0040-1712792 · Cited by 2
Advances & future prospects in newly diagnosed multiple myeloma patients
Hamadeh, I. S., Atrash, S., Fisher, A. M., Khan, M., Robinson, J., Paul, B., & Usmani, S. Z. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.96 · Cited by 1
Kado, Y., Tsujimoto, M., Fuchida, S., Okano, A., Hatsuse, M., Murakami, S., Sugii, H., Ueda, K., Toda, Y., Minegaki, T., et al. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00337 · Cited by 1
Recommendations on the management of multiple myeloma in 2020
Vekemans, M., Doyen, C., Caers, J., Wu, K., Kentos, A., Mineur, P., Michaux, L., Delforge, M., & Meuleman, N. (2020) · Acta Clinica Belgica · doi:10.1080/17843286.2020.1860411 · Cited by 2
“…Rd is associated with an improvement in PFS when compared to Rd given for a fixed duration of 18 months, a benefit even more prominent in patients achieving at least very good partial response (VGPR) [44], at the cost of more toxicities, particularly in the very old and frail population [30].”
BackgroundMethodSelf-citationBorgsten, F., Gatopoulou, X., Pisini, M., Tambour, M., Schain, F., Jones, C. V., Kwok, K. H. M., Batyrbekova, N., & Björkholm, M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13623 · Cited by 1
Induction Therapy Strategies in the Transplant-Ineligible Population
Attar, N., & O’Donnell, E. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000520 · Cited by 1
“4% for MPT.(15) Notably, the incidence of hematologic second primary malignancies was lower with continuous Rd than MPT.”
BackgroundInfluentialHernández‐Rivas, J., Arnao, M., Pérez, J. M. A., Rubio, A., García, E. G., de Miguel, D., Cherepanov, D., Romanus, D., Verleger, K., Johnson, C. W., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0301 · Cited by 1
Yoo, K. H., Yoon, D. H., Kang, H. J., Lee, W. S., Kım, K., Kim, J. S., Kim, J., Kim, S., Kwak, J., Kim, Y. S., et al. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100788 · Cited by 1
Self-citationGil‐Sierra, M. D., Briceño-Casado, M. D. P., Fenix-Caballero, S., Rey, E. J. A. D., de la Lastra‐Romero, C. A., & Sánchéz‐Hidalgo, M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211062144 · Cited by 2
Multiple Myeloma with a Special Focus on Precision Medicine
Schmidt, A. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.06.023 · Cited by 2
Hutchison, C. A., & Mollee, P. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-54945-5.00016-3 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Facon, T. T. F., & Manier, S. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.07.006 · Cited by 2
Self-citationChen, M.-T., Huang, S., Huang, H., Chen, W., Ko, B., & Hsiao, F. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02887-7 · Cited by 1
Bianchi, G., & Anderson, K. C. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch14 · Cited by 1
Self-citationEditorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
Milan, E., & Gullà, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264740 · Cited by 2
Manier, S., Lambert, J., Hulin, C., Macro, M., Laribi, K., Araujo, C., Pica, G. M., Touzeau, C., Godmer, P., Slama, B., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5201850 · Cited by 1
Self-citationTime to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
Mian, H. S., & Costa, L. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2604761 · Cited by 1
Schalhorn, B., & Hansen, T. (2014) · Im Focus Onkologie · doi:10.1007/s15015-014-1482-6
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.